For the quarter ending 2025-06-30, ATNF had -$2,366,810 decrease in cash & cash equivalents over the period.
| Cash Flow | 2025-06-30 |
|---|---|
| Shares issued for services | 676,456 |
| Prepaid expenses and other current assets | -408,440 |
| Accrued expenses related parties | 0 |
| Accounts payable | -17,007 |
| Accrued expenses | 629,157 |
| Accounts payable related parties | 409,251 |
| Change in fair value of derivative liabilities | 0 |
| Amortization of intangibles | 0 |
| Gain on settlement of liabilities | 0 |
| Amortization of stock options and restricted stock units | 4,752 |
| Total adjustments | 2,111,049 |
| Net loss | -4,095,836 |
| Net cash used in operating activities | -1,984,787 |
| Repayment of loans payable related parties | 350,000 |
| Repayment of loans payable | 3,320 |
| Proceeds from exercise of pre-funded warrants from the amendment to august 2023 offering | 0 |
| Net cash used in financing activities | -353,320 |
| Effect of exchange rate changes on cash | -28,703 |
| Net decrease in cash | -2,366,810 |
180 Life Sciences Corp. (ATNF)
180 Life Sciences Corp. (ATNF)